Ceelen W, Praet M, Villeirs G, Defreyne L, Pattijn P, Hesse U, de Hemptinne B
Department of Surgery, Gent University Hospital, Belgium.
Acta Chir Belg. 1996 Feb;96(1):37-40.
We retrospectively evaluated the influence of preoperative Transarterial Chemoembolization (TAE) on technique and complications, tumour histology, and disease-free survival after surgery for hepatic metastasis. In a 2-year period, a total of 23 patients were treated. In a first group of 14 patients, preoperative TAE was performed; in a second group of 9 patients only surgical resection was done. Extensive tumour necrosis was seen in the majority of patients treated with TAE; in tumours with an important fibrotic component, embolization was less effective. No significant effect was seen on operating time, transfusion requirement or perioperative complication rate. In the group of patients who underwent TAE, survival rate was 93% after a mean follow-up period of 15.5 months (SD: 12.5); recurrence was seen in only 8% of the survivors. In the second group, however, mortality was 33% after a median follow-up of 17.5 months (SD: 10), and recurrence was present in 66.7% of the survivors. These results indicate that preoperative TAE reduces the recurrence rate in the first postoperative year. Thereby survival may be improved in patients with resectable metastatic liver cancer.
我们回顾性评估了术前经动脉化疗栓塞术（TAE）对肝转移瘤手术的技术和并发症、肿瘤组织学以及无病生存期的影响。在两年时间里，共治疗了23例患者。第一组14例患者接受了术前TAE；第二组9例患者仅进行了手术切除。在大多数接受TAE治疗的患者中观察到广泛的肿瘤坏死；在具有重要纤维化成分的肿瘤中，栓塞效果较差。在手术时间、输血需求或围手术期并发症发生率方面未观察到显著影响。在接受TAE的患者组中，平均随访15.5个月（标准差：12.5）后生存率为93%；仅8%的幸存者出现复发。然而，在第二组中，中位随访17.5个月（标准差：10）后死亡率为33%，66.7%的幸存者出现复发。这些结果表明，术前TAE可降低术后第一年的复发率。从而可能改善可切除性转移性肝癌患者的生存率。
